Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00246467
Status:
COMPLETED
Last Update Posted:
2008-09-15
First Post:
2005-10-27
Brief Title:
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine rF1 and rV Antigens
Sponsor:
PharmAthene UK Limited
Organization:
PharmAthene UK Limited
Study Overview
Official Title:
A Phase 1b Multi-Centre Parallel Group Single Blind Study to Evaluate the Safety Tolerability and Immunogenicity of a Recombinant Plague Vaccine rF1 and rV Antigens in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
One hundred and five subjects will be recruited into three groups Each subject will receive two doses of recombinant plague vaccine at one of three dose levels rF1 and rV recombinant antigen proteins
Detailed Description:
Plague is an infection occurring in small rodents and mammals caused by the gram-negative bacterium Yersinia pestis Y pestis Transmission from rodent to man is usually by a flea vector leading to the characteristic swelling of the lymph nodes draining the region of the bite followed by a septicaemic illness classic bubonic plague Human-to-human transmission can occur via droplet nuclei spread by coughing of patients with bubonic or septicaemic plague who have developed pulmonary lesions pneumonic plague However cases of pulmonary transmission have also been described from household pets In pneumonic plague symptoms of a respiratory infection develop first followed by an acute onset septicaemic illness In the military context the likely exposure is via the inhalation route as a Biological Warfare Agent BWA and therefore protection against pneumonic plague is the paramount requirement This is a phase 1 parallel group single-blind study of 105 healthy adult aged 18-55 randomly assigned to one of the three cohorts and will receive the same dose of vaccines 2x and then re-randomized at 6 months to receive either a third dose or placebo in order to determine the safety and tolerability associated with different primary immunization doses of recombinant IM plague vaccine rF1 and rV antigen proteins for optimum safe dose assess responses both antibody and cell-mediated following immunization investigate the correlation between cell-mediated and antibody titers and to assess the duration of the immune responses to antigens following a third dose
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AVECrYP03 | None | None | None |